Bluejay Diagnostics Inc Dossier - Source-backed chat

Bluejay Diagnostics Inc

BJDXNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.91

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.85Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $875.5K

Enterprise Value −$8.7M

Shares Outstanding 1M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a late-stage, pre-revenue medical diagnostics company developing the Symphony™ platform, a near-patient testing system designed to deliver rapid, laboratory-quality results in critical care settings. The company's lead product candidate is an IL-6 test for sepsis triage and monitoring, which aims to provide results in approximately 24 minutes. While Bluejay has made significant operational progress—including enrolling approximately 680 out of 750 targeted patients in its SYMON-II pivotal trial and securing strategic manufacturing partnerships with Sanyoseiko and Argonaut Manufacturing Services—it remains a high-risk, pre-revenue entity. The company's financial position is highly constrained, with cash of $3.7 million as of March 31, 2026, and a history of substantial net losses ($6.85 million in FY2025). Although a recent private placement in June 2026 closed for up to $23.7 million (including upfront and warrant-associated proceeds), the company's long-term viability depends entirely on successful clinical validation, FDA 510(k) clearance, and subsequent commercial adoption. Consequently, a 'Hold' recommendation is advised until clinical data from the SYMON-II trial is locked and analyzed, and the regulatory pathway becomes clearer.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1720%

The bear case is triggered if the SYMON-II trial fails to validate the clinical utility of the IL-6 test, or if technical and quality issues with the Symphony cartridges persist despite partnerships with Sanyoseiko and Argonaut. This would lead to severe delays in regulatory submission or an outright rejection by the FDA. Given the company's limited cash runway and pre-revenue status, failure to achieve regulatory milestones would prevent the exercise of outstanding warrants, leading to severe liquidity crises, extreme shareholder dilution, or potential insolvency.

Base CaseCentral scenario

$4.2755%

The base case assumes Bluejay completes enrollment for the SYMON-II trial in mid-2026 and transitions to data analysis and cartridge validation. Manufacturing scale-up with Sanyoseiko and Argonaut progresses as planned, but analytical and clinical validation takes time, pushing the 510(k) regulatory submission to late 2027 or early 2028. The company continues to burn cash, requiring further dilutive capital raises or the exercise of outstanding warrants to fund operations through the regulatory review period. FDA clearance is eventually achieved, but commercialization is gradual, requiring significant sales and marketing investment.

Bull CaseUpside scenario

$13.1125%

The bull case assumes that Bluejay successfully completes the SYMON-II trial with positive clinical data that validates the IL-6 cutoff value for 28-day all-cause mortality in sepsis patients. Under this scenario, the strategic partnerships with Sanyoseiko and Argonaut successfully resolve previous cartridge manufacturing issues, enabling rapid analytical validation. The FDA grants 510(k) clearance ahead of schedule, allowing Bluejay to commercialize the Symphony platform in hospitals and long-term acute care (LTAC) settings. Rapid market adoption is driven by the platform's cost-effectiveness and 24-minute turnaround time, leading to robust revenue growth and a path to profitability.

Scenarios reflect our research view at the research date.

Key Investment Merits

Addressing a critical unmet need in sepsis triage and monitoring with a rapid, 24-minute near-patient testing platform.
Strong enrollment momentum in the SYMON-II pivotal clinical trial, with 680 of 750 patients enrolled as of May 2026.
Established strategic manufacturing partnerships with Sanyoseiko and Argonaut Manufacturing Services to secure scalable, high-quality cartridge production.
Substantial market opportunity in critical care and long-term acute care (LTAC) settings where rapid diagnostic turnaround is vital.

Key Investment Risks

Pre-revenue status with a history of operating losses ($6.95 million operating loss in FY2025) and high cash burn.
Significant regulatory risk, as the Symphony platform has not yet received FDA clearance and requires successful 510(k) submission.
Historical technical and quality challenges with Symphony cartridges, which are critical to the platform's clinical and commercial success.
High risk of ongoing shareholder dilution due to frequent capital raises, private placements, and outstanding warrants.

Thesis Invalidation Triggers

Failure of the SYMON-II trial to meet its primary clinical endpoints or validate the IL-6 cutoff for sepsis mortality.
Inability to resolve cartridge manufacturing quality and stability issues with Sanyoseiko or Argonaut.
FDA refusal to file or clear the 510(k) application for the Symphony IL-6 test.
Severe liquidity shortfall preventing the completion of clinical trials or regulatory submissions.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.